Paula
Rodríguez Otero
Consultora Médica
Oslo University Hospital
Oslo, NoruegaPublications in collaboration with researchers from Oslo University Hospital (11)
2024
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
2023
-
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
-
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))
Clinical Lymphoma, Myeloma and Leukemia
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83
2020
-
Melflufen for relapsed and refractory multiple myeloma
Expert Opinion on Investigational Drugs, Vol. 29, Núm. 10, pp. 1069-1078
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557